Table of Contents

H2 headings will appear here...

SUCCESS STATS

Drug Pathways & Tech

Updates to the SmithRx Low-Cost Insulin Program

Updates to the SmithRx Low-Cost Insulin Program

SmithRx

Key Takeaways
  • SmithRx Low-Cost Insulin Program promotes insulin lispro (generic) and insulin glargine-yfgn (biosimilar), enables pharmacist substitution, and passes 100% of savings to employer groups; lispro fills use SmithRx + Lilly cards to cap a month's supply at $35 or member copay.

  • Available at any SmithRx network pharmacy; contact help@smithrx.com.

Diabetes Continues To Be One Of The Highest (And Fastest Growing) Drug Spend Categories For Employer Groups

SmithRx is forging new pathways to make insulin more affordable. The SmithRx Low Cost Insulin Program decreases the cost of insulin at the pharmacy for employer groups and members.

All the savings from filling preferred generic and biosimilar insulins through this program are passed along to the employer group. Humalog is a rapid-acting/mealtime insulin and is available in the generic formulation, Insulin lispro. A long-acting insulin, Insulin glargine-yfgn is a biosimilar to and interchangeable with Lantus.

Lilly is the maker of Humalog and offers the generic formulation, insulin lispro. Pharmacists can substitute generic drugs for brand-name drugs. This program lowers the cost of rapid-acting Insulin lispro at the pharmacy by applying a savings card to the lesser of the member’s standard copay or $35 for a month’s supply.

Insulin glargine-yfgn is made by Mylan and is a biosimilar to and interchangeable with Lantus. In most states, the pharmacist can substitute Lantus for Insulin glargine-ygfn without a new prescription. By switching to biosimilar insulin products, this program provides up-front savings and at SmithRx we pass 100% of the savings to employer groups.

What Is A Biosimilar? How Is It Different From A Generic?

Biosimilar is a term used for a drug, like Insulin glargine-yfgn, that has no meaningful clinical differences from an existing biological drug, like Lantus. Biosimilars are reviewed and approved by the Food and Drug Administration (FDA) for clinical performance, safety, potency, and purity. Biosimilars are not considered generics by the FDA because they are made differently from the product they are being compared to despite having similar effectiveness and safety. Not all biosimilars are interchangeable and must meet additional testing requirements to show they are the same, clinically, in any given patient for the same indications. Insulin glargine-yfgn is interchangeable with Lantus.

These insulins can be filled at any pharmacy within the SmithRx network. For Insulin lispro, members must ask the pharmacist to run their insulin claim through their SmithRx card and their Lilly Savings Card.

Interested in learning more about how your clients can benefit from SmithRx’s Diabetes Low-Cost Insulin Program or our other Connect 360 programs? Get in touch!

SmithRx

SmithRx is the #1 Modern PBM, relentlessly focused on eliminating the conflicts and complexity of legacy pharmacy benefits. Built on radical transparency and fiduciary alignment, we empower employers to take control of their pharmacy spend and experience with our 100% pass-through model.

Drug Pathways & Tech

Why We’re Rebranding Connect 360 to Drug Pathways

We’re retiring the Connect 360 name and folding everything into what it actually is: Drug Pathways, powered by our Drug Pathways Engine. Here is exactly what this change means for you, your plan, and your members (spoiler: it’s all good news).

date

Drug Pathways & Tech

Why We’re Rebranding Connect 360 to Drug Pathways

We’re retiring the Connect 360 name and folding everything into what it actually is: Drug Pathways, powered by our Drug Pathways Engine. Here is exactly what this change means for you, your plan, and your members (spoiler: it’s all good news).

date

Abstract overhead view of interconnected circular nodes on a blue background, with one orange node at the center of a hub-and-spoke pattern

Drug Pathways & Tech

Aligned by Design: What Purpose-Built AI Looks Like in Modern Pharmacy Benefits

Not all AI is built the same. SmithRx VP of Engineering Gaston Concilio breaks down what purpose-built AI actually looks like in pharmacy benefits.

date

Abstract overhead view of interconnected circular nodes on a blue background, with one orange node at the center of a hub-and-spoke pattern

Drug Pathways & Tech

Aligned by Design: What Purpose-Built AI Looks Like in Modern Pharmacy Benefits

Not all AI is built the same. SmithRx VP of Engineering Gaston Concilio breaks down what purpose-built AI actually looks like in pharmacy benefits.

date

Drug Pathways & Tech

How Technology is Bringing ‘Humanity’ Back to Pharmacy Benefits

SmithRx CTO Bhavini Soneji explores how AI and modern platform architecture are redefining what makes a PBM. Discover how a "human-first" tech strategy delivers exceptional savings and scalability while deepening empathy in healthcare.

date

Drug Pathways & Tech

How Technology is Bringing ‘Humanity’ Back to Pharmacy Benefits

SmithRx CTO Bhavini Soneji explores how AI and modern platform architecture are redefining what makes a PBM. Discover how a "human-first" tech strategy delivers exceptional savings and scalability while deepening empathy in healthcare.

date

SmithRx is on a mission to reduce the complexity and costs of pharmacy benefits with radical transparency and cutting-edge technology.

Pharmacy and Provider Line
Member Help

M-F 8am - 9pm ET; Saturday 9am - 7pm ET

© 2026 Smith Health, Inc

SmithRx is on a mission to reduce the complexity and costs of pharmacy benefits with radical transparency and cutting-edge technology.

Pharmacy and Provider Line
Member Help

M-F 8am - 9pm ET; Saturday 9am - 7pm ET

© 2026 Smith Health, Inc

SmithRx is on a mission to reduce the complexity and costs of pharmacy benefits with radical transparency and cutting-edge technology.

Pharmacy and Provider Line
Member Help

M-F 8am - 9pm ET; Saturday 9am - 7pm ET

Company

Resources

Connect

© 2026 Smith Health, Inc